Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 2
2011 1
2012 1
2015 1
2016 1
2018 1
2019 2
2020 2
2021 3
2022 7
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, Babushok DV, Maillard IP, Carroll MP, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Paralkar VR, Bruno XJ, Hwang WT, Margolis D, Pratz KW. Matthews AH, et al. Among authors: martin me. Blood Adv. 2022 Jul 12;6(13):3997-4005. doi: 10.1182/bloodadvances.2022007265. Blood Adv. 2022. PMID: 35507945 Free PMC article.
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, Skuli S, Bruno XJ, Carroll MP, Freyer CW, Carulli A, Babushok DV, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Loren AW, Paralkar VR, Maillard IP, Pratz KW. Matthews AH, et al. Among authors: martin me. Am J Hematol. 2023 Aug;98(8):1254-1264. doi: 10.1002/ajh.26991. Epub 2023 Jun 19. Am J Hematol. 2023. PMID: 37334852 Free PMC article.
Characterization of Pericarditis following Allogeneic Hematopoietic Cell Transplantation.
Freyer CW, Fradley M, Madnick D, Carver JR, Frey NV, Gill SI, Ky B, Luger SM, Martin ME, McCurdy SR, O'Quinn R, Perl AE, Stadtmauer EA, Loren AW. Freyer CW, et al. Among authors: martin me. Transplant Cell Ther. 2021 Nov;27(11):934.e1-934.e6. doi: 10.1016/j.jtct.2021.07.025. Epub 2021 Jul 30. Transplant Cell Ther. 2021. PMID: 34339867 Free article.
Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation.
Freyer CW, Carulli A, Ganetsky A, Hughes ME, Krause TM, Timlin C, Frey NV, Gill SI, Hexner EO, Loren AW, Mangan JK, Martin ME, McCurdy SR, Perl AE, Pratz K, Porter DL, Luger SM. Freyer CW, et al. Among authors: martin me. Leuk Lymphoma. 2020 Sep;61(9):2200-2207. doi: 10.1080/10428194.2020.1765239. Epub 2020 Jun 1. Leuk Lymphoma. 2020. PMID: 32482107
OUTER RETINOPATHY AND MICROANGIOPATHY IN ACUTE MYELOGENOUS LEUKEMIA.
Miller CG, Brucker AJ, Perry LM, Kim BJ, Martin ME, Frey NV, Aleman TS. Miller CG, et al. Among authors: martin me. Retin Cases Brief Rep. 2023 Nov 1;17(6):683-689. doi: 10.1097/ICB.0000000000001294. Retin Cases Brief Rep. 2023. PMID: 37903306
Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant.
Hatch RV, Freyer CW, Carulli A, Redline G, Babushok DV, Frey NV, Gill SI, Hexner EO, Luger SM, Martin ME, McCurdy SR, Perl AE, Porter DL, Pratz KW, Stadtmauer EA, Loren AW. Hatch RV, et al. Among authors: martin me. J Oncol Pharm Pract. 2022 Jun;28(4):892-897. doi: 10.1177/10781552221080710. Epub 2022 Feb 22. J Oncol Pharm Pract. 2022. PMID: 35191732
Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
Graveno ME, Carulli A, Freyer CW, Mangan BL, Nietupski R, Loren AW, Frey NV, Porter DL, Gill SI, Hexner EO, Luger SM, Martin ME, McCurdy SR, Perl AE, Babushok DV, Pratz KW. Graveno ME, et al. Among authors: martin me. Leuk Lymphoma. 2022 Jul;63(7):1645-1650. doi: 10.1080/10428194.2022.2042688. Epub 2022 Mar 8. Leuk Lymphoma. 2022. PMID: 35259056
Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide.
Freyer CW, Carulli A, Gier S, Ganetsky A, Timlin C, Schuster M, Babushok D, Frey NV, Gill SI, Hexner EO, Luger SM, Mangan JK, Martin ME, McCurdy SR, Perl AE, Porter DL, Pratz K, Smith J, Stadtmauer EA, Loren AW. Freyer CW, et al. Among authors: martin me. Leuk Lymphoma. 2022 Aug;63(8):1925-1933. doi: 10.1080/10428194.2022.2042686. Epub 2022 Feb 20. Leuk Lymphoma. 2022. PMID: 35188052
25 results